Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer.

Trial Details

NCT ID
NCT07124858
Phase
NA
Sponsor
Federation Francophone de Cancerologie Digestive
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Fruquintinib
Locations (sample)
  • Poitiers, France, France|46.58261,0.34348
  • Albi, France|43.9298,2.148
  • Amiens, France|49.9,2.3
  • Annecy, France|45.90878,6.12565
  • Aurillac, France|44.92539,2.43983

Key Eligibility Criteria

  • Patients aged 18 and over.
  • Histologically confirmed colorectal adenocarcinoma with locally advanced disease and/or unresectable metastasis(es) receiving treatment with fruqui…
  • Obtain informed consent from the patient for the clinical-biological cohort.
  • Agreement to take biological samples of ctDNA and send tumour blocks (patient participation in the pharmacokinetic study remains optional).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →